Results from the Phase III VERITAC-2 trial demonstrated that vepdegestrant reduced the risk of disease progression or death ...

For patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast ...

Among patients with ESR1-mutant, ER+, HER2– advanced breast cancer, vepdegestrant improved survival without progression when ...

Vepdegestrant, an investigational estrogen receptor (ER) degrader, known as a proteolysis-targeting chimera (PROTAC ), ...

While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...

Vepdegestrant significantly improved outcomes for certain patients with ER-positive, HER2-negative advanced breast cancer ...

Arvinas (Nasdaq: ARVN) and Pfizer (NYSE: PFE) today announced detailed results from the Phase III VERITAC-2 clinical trial ...

Patients were randomly assigned in a 1:1 ratio to receive vepdegestrant at a dose of 200 mg orally once every day of each 28-day cycle or fulvestrant at a dose of 500 mg, administered ...

The investigational oral agent vepdegestrant more than doubled median progression-free survival (PFS) versus fulvestrant ...

Vepdegestrant, an oral PROTAC, nearly doubles progression-free survival in ESR1-mutated, ER-positive advanced breast cancer, ...

Arvinas noted that vepdegestrant, which is being developed alongside Pfizer to treat certain types of advanced or metastatic breast cancer, was generally well tolerated in the clinical trial, and that ...

Pfizer and Arvinas' experimental treatment significantly extends progression-free survival in breast cancer patients with ...